Sciences Ltd News Today

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) have been given an average rating of “Moderate Buy” by the ten research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. […]

Lobe Sciences (TSE:LOBE) has released an update. Lobe Sciences Ltd., a biopharmaceutical company, has announced a change of control after Clearway ...

This newsletter reports on U.S. legal matters relevant to Japanese companies. This edition covers U.S. court cases and cross-border transactions from the winter of 2023-24. Among other things...

Hyaluronic Acid Market by Application (Osteoarthritis, Cosmetics, Pharmaceutical API, Ophthalmology, Others), by End-Use Industry (Personal Care Industry, Pharmaceutical Industry, Others), and by Region (North America, South America, Europe, Asia Pac

Hyaluronic Acid Market by Application (Osteoarthritis, Cosmetics, Pharmaceutical API, Ophthalmology, Others), by End-Use Industry (Personal Care Industry, Pharmaceutical Industry, Others), and by Region (North America, South America, Europe, Asia Pac

Roivant Sciences (NASDAQ:ROIV – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report issued on Monday, Benzinga reports. They presently have a $18.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 64.53% from the company’s previous close. Other research analysts […]

Roivant Sciences (NASDAQ:ROIV – Free Report) had its price objective increased by Deutsche Bank Aktiengesellschaft from $14.00 to $15.00 in a report released on Wednesday, Benzinga reports. They currently have a buy rating on the stock. ROIV has been the subject of several other reports. Piper Sandler started coverage on Roivant Sciences in a research […]

Roivant Sciences (NASDAQ:ROIV – Free Report) had its price target upped by HC Wainwright from $17.00 to $18.00 in a research note released on Wednesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Roivant Sciences’ Q1 2025 earnings at ($0.25) EPS, Q2 2025 earnings […]

VANCOUVER, BC, April 2, 2024 /CNW/ - Filament Health Corp. , a clinical-stage natural psychedelic drug development company, released its fourth quarter financial results and operational highlights...

Detailed price information for Lennar Corp (LEN-N) from The Globe and Mail including charting and trades.